ライフサイエンスコーパス: neuromuscular blockade

1 rapy can be delivered without the need for a neuromuscular blockade.

2 x of whom required a subsequent surgery with neuromuscular blockade.

3 ble of rapid reversal of profound rocuronium neuromuscular blockade.

4 several years to control blood pressure and neuromuscular blockade.

5 ria and PaO2/FIO2 less than 150 who received neuromuscular blockade.

6 ays patients received sedatives, opioids, or neuromuscular blockade.

7 tulism, which is characterized by peripheral neuromuscular blockade.

8 ere was no difference in MEE with or without neuromuscular blockade.

9 n with severe lung disease or in those under neuromuscular blockade.

10 renic nerve-hemidiaphragm from toxin-induced neuromuscular blockade.

11 iratory distress syndrome patients receiving neuromuscular blockade.

12 ients with PaO2/FIO2 less than 150 receiving neuromuscular blockade.

13 oreal membrane oxygenation patients received neuromuscular blockade (46%) or were heavily sedated wit

14 ccinylcholine arguably remains the preferred neuromuscular blockade agent for rapid sequence intubati

15 pon the clinical scenario, and the choice of neuromuscular blockade agent.

16 on, acute associated nonpulmonary infection, neuromuscular blockade agents or nitric oxide use, bicar

17 Neuromuscular blockade alone does not cause hypothermia

18 With neuromuscular blockade and artificial ventilation, effer

19 stal nerves of T9 or T10 in adult rats, with neuromuscular blockade and artificial ventilation, under

20 e prevalence of neuromuscular weakness after neuromuscular blockade and of the costs to the healthcar

21 more severely hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have furthe

22 lly, methods to avoid entirely, or minimize, neuromuscular blockade and sedation are supported by rec

23 We wished to show that HO can occur after neuromuscular blockade and that these cases might provid

24 symptoms between the group that had received neuromuscular blockade and those who had not.

25 associated with higher PEEP, greater use of neuromuscular blockade, and prone positioning.

26 ong ICU variables (days of sedation, days of neuromuscular blockade, and severity of illness as measu

27 y distress syndrome receiving treatment with neuromuscular blockade because they cannot shiver.

28 as no difference in the need for sedation or neuromuscular blockade between the two tidal volume prot

29 be a useful tool for monitoring the depth of neuromuscular blockade but only if it is incorporated in

30 To investigate whether partial neuromuscular blockade can facilitate lung-protective ve

31 ient uncovered) or active (cooling blankets, neuromuscular blockade) cooling measures were used to ma

32 ce of food from a narrow food well, when the neuromuscular blockade dissipated (by week 10) and in ma

33 Traditionally, reversal of neuromuscular blockade during anaesthesia was achieved b

34 nts offer a new approach for the reversal of neuromuscular blockade: encapsulation of the neuromuscul

35 Partial neuromuscular blockade facilitates lung-protective venti

36 gated as a means of limiting the duration of neuromuscular blockade following rapid sequence inductio

37 nuous infusion of doxacurium provides stable neuromuscular blockade for neurosurgical patients with t

38 6-37.3 degrees C), and fever occurred during neuromuscular blockade in 30 of 58 retrospective patient

39 Eleven days of mechanical ventilation and neuromuscular blockade in healthy baboons resulted in no

40 in of four alone for monitoring the depth of neuromuscular blockade in patients receiving continuous

41 degree of shivering) to assess the degree of neuromuscular blockade in patients undergoing therapeuti

42 Neuromuscular blockade in the setting of ARDS appears to

43 Partial neuromuscular blockade increased heart rate, mean arteri

44 1) We make no recommendation as to whether neuromuscular blockade is beneficial or harmful when use

45 plete recovery from both normal and profound neuromuscular blockade is now possible.

46 ine use of quantitative monitors of depth of neuromuscular blockade is the best guarantee of the adeq

47 Neuromuscular blockade (NMB) reversal with neostigmine a

48 , 2.47; 95% confidence interval, 1.47-4.14), neuromuscular blockade (odds ratio, 4.98; 95% confidence

49 of sedation (p = .007), but not with days of neuromuscular blockade or initial severity of illness.

50 ser to threshold) during exercise by partial neuromuscular blockade (P < 0.05).

51 with days of sedation (p = .006) and days of neuromuscular blockade (p = .035), but not with initial

52 the protocol was repeated following partial neuromuscular blockade (PNB; i.v. cisatracurium).

53 can be managed with early short-term use of neuromuscular blockade, prone position ventilation, or e

54 elerating the time to single innervation and neuromuscular blockade retarding it.

55 ry visual cortex of anaesthetized cats under neuromuscular blockade, that contrast invariance occurs

56 ision of continuous analgesia, sedation, and neuromuscular blockade to critically ill patients requir

57 4) We make no recommendation on the use of neuromuscular blockade to improve the accuracy of intrav

58 : control (no intervention) and with partial neuromuscular blockade (to increase central command infl

59 Patients with intermittent neuromuscular blockade use (n = 4) had higher FIO2 (0.65

60 Use of prone positioning and neuromuscular blockade was significantly more common in

61 Onset, maintenance, and recovery of neuromuscular blockade were measured, using transcutaneo

62 Deeper sedation and intermittent neuromuscular blockade were used for patients with great

63 ctors (tracheal intubation method and use of neuromuscular blockade) were recorded.

64 weakness after continuous, nondepolarizing, neuromuscular blockade with a group of controls without

65 cardiac arrest followed asphyxia produced by neuromuscular blockade with and without airway obstructi

66 ine and prone positions in 30 patients under neuromuscular blockade with lung disorders including mod

67 ive drugs should be used prior to and during neuromuscular blockade, with the goal of achieving deep

68 ntrol static and dynamic exercise by partial neuromuscular blockade without alterations in gain (P <